MedTrace Logo

GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia

NCT04569877 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2023-05-10

No results posted yet for this study

Summary

To assess the safety and tolerability of inhaled molgramostim nebuliser solution in patients with COVID-19 pneumonia.

Conditions

Interventions

DRUG

Molgramostim nebuliser solution

300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system

OTHER

Placebo nebuliser solution

Placebo nebulised seven times within 7 days via rapid nebuliser system

Sponsors & Collaborators

  • University of Giessen

    lead OTHER

Principal Investigators

  • Susanne Herold, Prof. Dr. · Universitätsklinikum Giessen und Marburg (UKGM)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-24
Primary Completion
2022-06-21
Completion
2022-09-20

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569877 on ClinicalTrials.gov